Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Next Previous
Drug Profile

Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Alternative Names: CDK4 inhibitors - Onconova; ON 108110; ON 108600; ON-123300; ON-150030

Latest Information Update: 24 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onconova Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Onconova Therapeutics
  • Class Antineoplastics; Pyrimidines; Thiazines
  • Mechanism of Action Casein kinase II inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors; Germinal centre kinase inhibitors; NUAK1 protein inhibitors; PIM3 protein inhibitors; Protein tyrosine kinase inhibitors; Protein-serine-threonine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Colorectal cancer
  • Research Breast cancer
  • No development reported Cancer

Most Recent Events

  • 15 Jan 2019 Onconova Therapeutics plans a clinical trial in first half of 2019
  • 13 Nov 2018 Onconova Therapeutics plans to file IND for ON 123300 in the first half of 2019
  • 19 Apr 2018 Onconova Therapeutics and HanX Biopharmaceuticals announce intention to submit IND application for ON 123300 in USA and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top